QT Vascular has announced that it has entered into an asset purchase option agreement with Medtronic, for the acquisition of the non-drug coated Chocolate PTA.
“Chocolate represents a breakthrough in percutaneous transluminal angioplasty design. Its unique nitinol constraining structure is designed to provide atraumatic dilatation in the treatment of blocked arteries. Less trauma translates to better acute results, QT Vascular states on its marketing materials.
Independently, QT Vascular will continue to develop and market its other products including a drug-coated version of Chocolate PTA, Chocolate Touch, which has received investigational device exemption approval from the US FDA and its coronary products portfolio of both drug and non-drug coated products. QT Vascular is based in Singapore with a US subsidiary, Trireme Medical.
QT Vascular develops and commercialises of next-generation minimally invasive products for the treatment of complex vascular disease. It works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.
